Journal article
Changes in plasma lipids predict pravastatin efficacy in secondary prevention
KS Jayawardana, PA Mundra, C Giles, CK Barlow, PJ Nestel, EH Barnes, A Kirby, P Thompson, DR Sullivan, ZH Alshehry, NA Mellett, K Huynh, MJ McConville, S Zoungas, GS Hillis, J Chalmers, M Woodward, IC Marschner, G Wong, BA Kingwell Show all
Jci Insight | AMER SOC CLINICAL INVESTIGATION INC | Published : 2019
Open access
Abstract
BACKGROUND. Statins have pleiotropic effects on lipid metabolism. The relationship between these effects and future cardiovascular events is unknown. We characterized the changes in lipids upon pravastatin treatment and defined the relationship with risk reduction for future cardiovascular events. METHODS. Plasma lipids (n = 342) were measured in baseline and 1-year follow-up samples from a Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study subcohort (n = 4991). The associations of changes in lipids with treatment and cardiovascular outcomes were investigated using linear and Cox regression. The effect of treatment on future cardiovascular outcomes was examined by the..
View full abstractGrants
Awarded by NHMRC
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
The LIPID study was supported by Bristol-Myers Squibb and the NHMRC (grants 211086, 358395). JC and MW are supported by an NHMRC program grant (1149987) and MW by an NHMRC fellowship (108026). This study was supported by an NHMRC grant (1029754) and the Operational Infrastructure Support Program of the Victorian government of Australia. We would like to thank the investigators of the LIPID and the ADVANCE studies and the patients who participated in these studies. We acknowledge Michelle Cinel and Ricardo Tan for their technical support in the lipidomic analyses. See the Supplemental Acknowledgments for the LIPID Study Investigators' details.